A 69-year-old woman was referred to our department for evaluation of hypokalemia, which had been treated by oral potassium for more than ten years. She complained of headache, knee joint pain, sleeplessness and paresthesia in extremities and, most prominently, depression. Laboratory data suggested Gitelman's syndrome, which is caused by mutations in the gene encoding the thiazide-sensitive Na-Cl cotransporter. 
Introduction
Gitelman's syndrome (GS) was first characterized in 1966 by hypokalemia, metabolic alkalosis, and normal blood pressure under hyperreninaemic hyperaldosteronism, concomitant with hypocalciuria and hypomagnesaemia (1) . GS was thought to be a variant of Bartter's syndrome, but is now recognized as an autosomal recessive disorder due to mutations in the gene (SLC12A3) encoding the thiazide-sensitive Na-Cl cotransporter (TSC) (2) . This gene lies on chromosome 16q13 and has 26 exons encoding a polypeptide of 1,021 amino acids consisting of 12 transmembrane domains. TSC is expressed in the renal distal convoluted tubule, molecular defects in which cause hypokalemia and hypocalciuria similar to that seen in patients treated with thiazide diuretics. Hypomagnesemia also is common in these patients, possibly due to magnesium wasting by urinary excretion.
The clinical symptoms of GS such as episodic muscular weakness, tetany, abdominal pain, and fatigue or joint pain are not as severe or as frequent as in Bartter's syndrome. Asymptomatic adults sometimes have hypokalemia, but the mildness of the symptoms hampers diagnosis. Here, we report a case of GS with severe depression and paresthesia lasting for more than ten years which was dramatically improved by intravenous magnesium sulfate (MgSO4) treatment.
Case Report
A 69-year-old woman presented with an egg-size mass in her left axilla in October 2001. She had had an operation for malignant melanoma on her back in 1988, and the mass was diagnosed as lymph node metastasis by excisional biopsy. She was admitted to the department of dermatology in our hospital for chemotherapy in February 2002, and then was moved to the third department of internal medicine for evaluation of hypokalemia of unknown origin in April 2002.
The patient had no history of chronic diarrhea, vomiting or diuretics use. She complained of headache, joint pain of bilateral knees, sleeplessness, and paresthesia in extremities. There was no history of tetany or palsy, but physical examination showed grip test at 7.2 kg bilaterally. She had an attack of muscle weakness after hospitalization, which was Table 1 . The plasma potassium level was low despite daily supplementation of 32 mEq potassium chloride, but urinary excretion of potassium was not decreased. The patient had hypomagnesemia, hypocalciuria, and metabolic alkalosis. Plasma renin and aldosterone levels were high. X-rays of bilateral knees revealed chondrocalcinosis of the menisci. All these features are consistent with a diagnosis of GS. Bettinelli et al have described the following criteria: 1) hypomagnesemia (<0.65 mmol/l) in the presence of inappropriately high magnesium excretion (fractional excretion of magnesium >4.0%); 2) hypokalemia (<3.6 mmol/l) in the presence of inappropriately high potassium excretion (fractional excretion of potassium >16.0%); and 3) urinary calcium/creatinine molar ratio <0.10 (3). The laboratory data of the present case concur with these criteria except for the urinary calcium/creatinine molar ratio, which was 0.15. To evaluate distal nephron function, the effects of furosemide (FUR) and hydrochlorothiazide (HCT) were examined according to the study protocol described previously (4). We used 10 mg FUR injected intravenously and 100 mg HCT administered orally. After maximal diuresis induced by oral water intake and drip infusion of half of the saline, electrolyte excretion was evaluated as fractional clearance (FEx. i.e., Cx/GFR) using creatinine clearance (Ccr) as GFR marker. After FUR administration, there were obvious increases in both FENa and FECl but only small increases after HCT administration. Colussi et al reported that in healthy adults, differences in maximal Na and Cl excretion between before and after HCT administration were 2.52±1.14% and 3.64±1.30 %, respectively (5) . In this case they were 1.7% and 1.2%. In addition, fractional free water clearance (CH 2 O/ CH 2 O+CCl ) as a fraction of distal delivery showed an abrupt change after FUR administration while HCT induced little effect (Figs. 1  and 2 ).
Genetic analysis was performed after obtaining informed consent. Direct sequencing of the exons and flanking introns of SLC12A3 revealed homozygous mutation R964Q (CGG CAG) in exon 25, confirming the diagnosis of GS in this patient (Fig. 3) . This mutation corresponds to R955Q that Simon et al reported in a Japanese patient (6) ; the different numbering of the amino acid residues may be due to possible splicing variation. We were unable to examine other family members. Therapy with spironolactone (25 mg/day) and oral magnesium (magnesium oxide 1.5 g/day) was begun in addition to the potassium chloride supplementation (16 mEq/day). However, because of the severe diarrhea, the magnesium dosage had to be reduced to 0.5 g/day. For the persisting hypomagnesemia, intravenous drip infusion of magnesium sulfate (20 mEq/day) dissolved in 100 ml normal saline was performed for three days. As hypermagnesemia may cause Mg toxicity (specific symptoms so far reported are nausea, vomiting, muscle weakness, reduction of deep tendon reflexes, respiratory paralysis and cardiac arrest), MgSO4 was administered for over two hours. On the second day of intravenous magnesium supplementation, the patient's depressive state improved dramatically, and she became quite active. The paresthesia in her extremities disappeared completely (Fig. 4) . Intravenous drip infusion of magnesium at least once a week was required to maintain the serum magnesium level.
Discussion
Gitelman's syndrome has been considered a variant of Bartter's syndrome because of similarities in both clinical features and laboratory data. In 1996, Simon et al demonstrated complete linkage of GS to the locus including SLC12A3 and identified mutations in this gene in GS patients (6) . Thirty Japanese families have been described in the literature; the male to female ratio is 3 : 4 and the age at diagnosis ranges from 5 to 66 years with a mean of 28.4 years.
Gene testing was performed in thirteen of these families to confirm the diagnosis, resulting in the identification of fifteen different mutations including four compound heterozygotes. The most frequent clinical symptoms observed in patients are tetany and cramp (n=8), followed by muscle weakness and paralysis (n=7) and fatigue (n=6). The others are numbness, nausea, vomiting, abdominal pain, diarrhea, joint pain, growth retardation, dyspnea, and unstable feeling (4, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . The depressive state seen in this case is not common. The medical record shows that the patient had hypokalemia (2.5 mEq/l) in 1988, but the plasma magnesium level was not examined due to the absence of the typical symptoms.
Treatment with spironolactone and/or oral administration of potassium and magnesium is commonly performed in patients with GS. Spironolactone with supplementation of potassium chloride corrected the hypokalemia in this patient but did not relieve the symptoms. In contrast, intravenous magnesium supplementation promptly improved her condition, suggesting that the hypomagnesemia had played a major role in her clinical manifestations. Of patients who have received diagnostic gene testing, this is the only case of intravenous magnesium supplementation. Magnesium is an essential cation involved in a wide range of biological activities and plays crucial roles in many enzymatic systems. Hypomagnesemia, therefore, is associated with multiple nonspecific clinical symptoms and signs (23) , and the variety often results in confusion and controversy in diagnosis. As in this patient at an earlier stage, GS presents only mild clinical features or remains asymptomatic. In addition, because serum magnesium is not measured routinely in clinics, many patients with GS are not diagnosed. Accordingly, patients with hypokalemia of unknown origin should be checked for the presence of hypomagnesemia and hypocalciuria.
To date, a number of different TSC mutations have been reported (2, 6, 18, (24) (25) (26) (27) (28) . They include missense, frameshift, nonsense and splice-site mutations distributed throughout the entire coding region of the protein. Our patient had a missense mutation in the intracellular carboxyl terminus that contains a putative cAMP-dependent protein kinase phosphorylation site, a putative protein kinase C phosphorylation site, and two putative casein kinase phosphorylation sites (2) . Functional analysis of the mutant protein identified in our patient should clarify the physiological properties of this domain and lead to a better understanding of the pathogenesis, genotype/phenotype relationship, and therapeutic significance of magnesium supplementation. 
